Brokerages Set uniQure (NASDAQ:QURE) Price Target at $19.50

Shares of uniQure (NASDAQ:QURE) have been assigned an average rating of “Moderate Buy” from the six brokerages that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $19.50.

A number of equities analysts have commented on the stock. The Goldman Sachs Group upped their price objective on shares of uniQure from $6.00 to $10.00 and gave the stock a “neutral” rating in a research report on Friday, August 2nd. HC Wainwright restated a “buy” rating and issued a $25.00 price objective on shares of uniQure in a research report on Tuesday, August 20th. Raymond James reaffirmed an “outperform” rating and issued a $20.00 price objective on shares of uniQure in a report on Thursday, October 10th. StockNews.com raised uniQure to a “sell” rating in a research note on Thursday, October 17th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $28.00 price target on shares of uniQure in a research note on Friday, September 20th.

uniQure Stock Up 2.4 %

QURE opened at $5.86 on Friday. uniQure has a 52 week low of $3.73 and a 52 week high of $11.35. The business has a 50 day moving average price of $5.69 and a two-hundred day moving average price of $5.75. The company has a quick ratio of 7.36, a current ratio of 7.36 and a debt-to-equity ratio of 1.06. The company has a market cap of $285.38 million, a PE ratio of -0.99 and a beta of 0.95.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($1.16) EPS for the quarter, topping the consensus estimate of ($1.24) by $0.08. uniQure had a negative return on equity of 158.09% and a negative net margin of 1,027.52%. The business had revenue of $11.13 million during the quarter, compared to analysts’ expectations of $3.47 million. As a group, research analysts anticipate that uniQure will post -4.1 EPS for the current year.

Institutional Investors Weigh In On uniQure

A number of institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Personalized Indexing Management LLC boosted its position in uniQure by 21.0% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 2,306 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of uniQure by 57.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after buying an additional 3,663 shares during the last quarter. American Century Companies Inc. boosted its position in shares of uniQure by 14.6% in the 2nd quarter. American Century Companies Inc. now owns 67,699 shares of the biotechnology company’s stock worth $303,000 after buying an additional 8,642 shares in the last quarter. Atria Investments Inc acquired a new stake in uniQure in the 3rd quarter valued at about $53,000. Finally, Clear Harbor Asset Management LLC increased its holdings in uniQure by 35.2% during the 2nd quarter. Clear Harbor Asset Management LLC now owns 48,000 shares of the biotechnology company’s stock valued at $215,000 after acquiring an additional 12,500 shares in the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.